Erlotinib (2)

Pharmacogenomic Information

DrugTherapeutic Area*BiomarkerReferenced
Labeling Sections
ErlotinibOncologyEGFREGFR exon 19
deletion or
exon 21 substitution
(L858R) positive

Indications and Usage
Dosage and Administration, Adverse Reactions, Clinical Pharmacology
Clinical Studies


* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 03/17/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.